Link to this page
Physician Data Query
| Preferred Name | alendronate sodium | |
| Synonyms |
Binosto Fosamax Alendronic Acid Monosodium Salt Trihydrate MK 217 Adronat G-704650 Alendros MK-217 Alendronate Onclast |
|
| Definitions |
The sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C973" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C973" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000041299 |
|
| altLabel |
Binosto Fosamax Alendronic Acid Monosodium Salt Trihydrate MK 217 Adronat G-704650 Alendros MK-217 Alendronate Onclast
|
|
| CAS Registry |
129318-43-0
|
|
| Component of | ||
| cui |
C3268148 C0376569 C4316846 C1510842 C1521992 C1510843 C0700482 C0047995 C0102118 C1510841
|
|
| Date last modified |
2016-07-29
|
|
| definition |
The sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C973" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C973" NCI Thesaurus)
|
|
| Legacy PDQ ID |
4372
|
|
| LT |
TRD
|
|
| NCI ID |
C973
|
|
| notation |
CDR0000041299
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
alendronate sodium
|
|
| tui |
T109 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |